Next-Generation Antibody Therapeutics Market Report 2026

Next-Generation Antibody Therapeutics Market Overview

• Next-Generation Antibody Therapeutics market size has reached to $7.56 billion in 2025 • Expected to grow to $12.63 billion in 2030 at a compound annual growth rate (CAGR) of 10.9% • Growth Driver: Next-Generation Antibody Therapeutics Is A Vital Solution In Addressing The Surge Of Chronic Diseases • Market Trend: Revolutionizing Antibody Therapeutics By Exploring Cutting-Edge Technologies And Breakthroughs In Next-Generation Solutions • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Next-Generation Antibody Therapeutics Market?

Next-generation antibody therapeutics are advanced antibody-based drugs in structure, functionality, and therapeutic potential beyond traditional monoclonal antibodies. It treats several severe medical problems, including cancer, infectious infections, and immunological disorders. The main types of antibodies in next-generation antibody therapeutics are monoclonal antibodies, polyclonal antibodies, biospecific antibodies, antibody-drug conjugates, and others. Monoclonal antibodies refer to a particular kind of laboratory-produced protein that can bind to certain bodily targets, such as antigens on the surface of cancer cells. The various therapeutic areas are oncology, autoimmune diseases, infectious diseases, neurodegenerative disorders, and others used in hospitals and clinics, research institutes, pharmaceutical and biotechnology companies, and others.

What Is The Next-Generation Antibody Therapeutics Market Growth Forecast?

The next-generation antibody therapeutics market size is expected to see rapid growth in the next few years. It will grow to $12.63 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to advancement in antibody engineering technologies, rising demand for targeted therapies, increasing incidence of chronic and autoimmune diseases, expansion of clinical trials in emerging markets, growing partnerships between biotech and pharma companies. Major trends in the forecast period include expansion of bispecific and multispecific antibody platforms, growing adoption of antibody-drug conjugates in oncology, increased focus on high-affinity and long-acting antibodies, rising clinical pipeline for rare and orphan diseases, shift toward personalized antibody-based therapies.

Global Next-Generation Antibody Therapeutics Market Segmentation

1) By Types Of Antibodies: Monoclonal Antibodies, Polyclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Types 2) By Therapeutic Area: Oncology, Autoimmune Diseases, Infectious Diseases, Neurodegenerative Disorders, Other Therapeutic Areas 3) By End-User: Hospitals And Clinics, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End-Users Subsegments: 1) By Monoclonal Antibodies: IgG Monoclonal Antibodies, IgM Monoclonal Antibodies 2) By Polyclonal Antibodies: Serum-Derived Polyclonal Antibodies, Hybridoma-Derived Polyclonal Antibodies 3) By Bispecific Antibodies: Dual-Targeting Antibodies, Single-Chain Variable Fragment (scFv) Antibodies 4) By Antibody-Drug Conjugates (ADCs): Targeted ADCs, Payload Types 5) By Other Types: Nanobodies, Engineered Antibodies

What Is The Driver Of The Next-Generation Antibody Therapeutics Market?

The increasing prevalence of chronic diseases is expected to propel the growth of the next-generation antibody therapeutics market going forward. Chronic diseases are problems that last a year or longer, necessitating continuing medical care, restricting everyday activities, or both. Next-generation antibody therapeutics have a therapeutic function for individuals with chronic illnesses that deliver more focused care, which would benefit patients’ outcomes. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, it was projected that by the year 2050, the number of individuals aged 50 years and older who have at least one chronic illness will surge by 99.5%, rising to 142.66 million. Therefore, the increasing prevalence of chronic diseases is driving the growth of the next-generation antibody therapeutics industry.

Key Players In The Global Next-Generation Antibody Therapeutics Market

Major companies operating in the next-generation antibody therapeutics market are Pfizer Inc., F. Hoffmann‑La Roche Ltd., Bristol‑Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Genentech Inc., Kyowa Hakko Kirin Co. Ltd., Seagen Inc., Seattle Genetics Inc., Xencor Inc., ImmunoGen Inc., Genmab A/S, Zymeworks Inc., NBE‑Therapeutics AG, Daiichi Sankyo Company Limited, Merck & Co Inc., Novartis AG, AbCellera Biologics Inc., Sotio Biotech, F‑Star Therapeutics Ltd., ADC Therapeutics SA, Harbour BioMed

Global Next-Generation Antibody Therapeutics Market Trends and Insights

Major companies operating in the next-generation antibody therapeutics market are focused on developing technological advancements such as proprietary Molecular Indexing of Proteins by Self-Assembly (MIPSA) technology to enhance protein identification and characterization, leading to more targeted and effective treatments. As a result, these advancements aim to improve therapeutic profiles, reduce costs, and address complex diseases with greater precision. Molecular Indexing of Proteins by Self-Assembly (MIPSA) is a technology that organizes protein molecules into structured assemblies for enhanced analysis and quantification. It improves sensitivity and accuracy in protein detection, useful in research and diagnostics. For instance, in January 2024, Infinity Bio, Inc., a US-based biotechnology company, launched a next-generation antibody profiling platform, that utilizes MIPSA technology for high-throughput, cost-effective analysis of immune responses, aiming to enhance disease understanding and personalize treatment strategies.

What Are Latest Mergers And Acquisitions In The Next-Generation Antibody Therapeutics Market?

In February 2024, AbbVie Inc., a US-based pharmaceutical company, acquired ImmunoGen, Inc. for approximately US$10.1 billion. Through this acquisition, AbbVie aims to enhance its next-generation antibody therapeutic capabilities by integrating ImmunoGen’s folate receptor-alpha–targeted antibody-drug conjugate, ELAHERE approved for platinum-resistant ovarian cancer and by expanding its pipeline of antibody-drug conjugates across solid tumors and hematologic malignancies. ImmunoGen, Inc. is a US-based biotechnology company specializing in the development of innovative antibody-drug conjugate platforms for oncology.

Regional Outlook

North America was the largest region in the next-generation antibody therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Next-Generation Antibody Therapeutics Market?

The next-generation antibody therapeutics market consists of revenues earned by entities by providing services such as antibody engineering, antibody manufacturing, and regulatory support. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation antibody therapeutics market also includes sales of immune checkpoint inhibitors, antibody-targeted nanoparticles, and antibody-mimetic proteins. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Next-Generation Antibody Therapeutics Market Report 2026?

The next-generation antibody therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the next-generation antibody therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.